Themis: advancing precision oncology through comprehensive molecular subtyping and optimization
Related Experiment Video
Updated: Jun 24, 2025
Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
Published on: April 11, 2016
Yue Xi1,2, Kun Zheng3, Fulan Deng4
1Department of Reproductive Medicine, Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong Province, 250013, China.
Abstract:
Recent advances in tumor molecular subtyping have revolutionized precision oncology, offering novel avenues for patient-specific treatment strategies. However, a comprehensive and independent comparison of these subtyping methodologies remains unexplored. This study introduces 'Themis' (Tumor HEterogeneity analysis on Molecular subtypIng System), an evaluation platform that encapsulates a few representative tumor molecular subtyping methods, including Stemness, Anoikis, Metabolism, and pathway-based classifications, utilizing 38 test datasets curated from The Cancer Genome Atlas (TCGA) and significant studies. Our self-designed quantitative analysis uncovers the relative strengths, limitations, and applicability of each method in different clinical contexts. Crucially, Themis serves as a vital tool in identifying the most appropriate subtyping methods for specific clinical scenarios. It also guides fine-tuning existing subtyping methods to achieve more accurate phenotype-associated results. To demonstrate the practical utility, we apply Themis to a breast cancer dataset, showcasing its efficacy in selecting the most suitable subtyping methods for personalized medicine in various clinical scenarios. This study bridges a crucial gap in cancer research and lays a foundation for future advancements in individualized cancer therapy and patient management.
Insights
A new platform, Themis, evaluates tumor molecular subtyping methods for precision oncology. It identifies the best methods for specific clinical scenarios, improving patient-specific treatment strategies and cancer therapy.
Area of Science:
- Oncology
- Bioinformatics
- Computational Biology
Background:
- Precision oncology relies on accurate tumor molecular subtyping for tailored treatments.
- Existing subtyping methods lack comprehensive, independent comparative analysis.
- This gap hinders optimal selection and refinement of subtyping strategies.
Purpose of the Study:
- Introduce Themis (Tumor HEterogeneity analysis on Molecular subtypIng System), an evaluation platform for tumor molecular subtyping methods.
- Quantitatively compare representative subtyping methodologies.
- Provide guidance for selecting and refining methods for clinical application.
Main Methods:
- Developed Themis, an evaluation platform for tumor molecular subtyping.
- Included methods: Stemness, Anoikis, Metabolism, and pathway-based classifications.
- Utilized 38 diverse datasets from The Cancer Genome Atlas (TCGA) and other key studies.
Main Results:
- Uncovered relative strengths, limitations, and applicability of different subtyping methods.
- Demonstrated Themis's capability to identify optimal methods for specific clinical contexts.
- Showcased practical utility through a breast cancer dataset analysis.
Conclusions:
- Themis is a vital tool for selecting appropriate molecular subtyping methods in oncology.
- The platform facilitates the fine-tuning of methods for improved phenotype-associated results.
- This work advances individualized cancer therapy and patient management strategies.
More Related Videos
03:49Author Spotlight: Enhancing Nuclei Isolation for Multiome Sequencing in Challenging Tumor Microenvironments
Published on: October 13, 2023
13:01Industrialized, Artificial Intelligence-guided Laser Microdissection for Microscaled Proteomic Analysis of the Tumor Microenvironment
Published on: June 3, 2022
